# SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

> **NCT02334865** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 18 (actual)

## Conditions studied

- Partial Response of Multiple Myeloma or Plasma Cell Leukemia
- Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Incomplete Freund's Adjuvant
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide
- **BIOLOGICAL:** Sargramostim
- **BIOLOGICAL:** SVN53-67/M57-KLH Peptide Vaccine

## Key facts

- **NCT ID:** NCT02334865
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-04-13
- **Primary completion:** 2022-09-16
- **Final completion:** 2026-12-19
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02334865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02334865, "SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02334865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*